14-50587992-G-C
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 1P and 10B. PP2BP4BP6BS1BS2
The NM_015915.5(ATL1):c.196G>C(p.Glu66Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000638 in 1,614,064 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E66K) has been classified as Uncertain significance.
Frequency
Consequence
NM_015915.5 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 3AInheritance: AD, SD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
 - neuropathy, hereditary sensory, type 1DInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae)
 - hereditary sensory and autonomic neuropathy type 1Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -9 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| ATL1 | NM_015915.5  | c.196G>C | p.Glu66Gln | missense_variant | Exon 2 of 14 | ENST00000358385.12 | NP_056999.2 | |
| ATL1 | NM_001127713.1  | c.196G>C | p.Glu66Gln | missense_variant | Exon 3 of 14 | NP_001121185.1 | ||
| ATL1 | NM_181598.4  | c.196G>C | p.Glu66Gln | missense_variant | Exon 2 of 13 | NP_853629.2 | ||
| ATL1 | XM_047431430.1  | c.196G>C | p.Glu66Gln | missense_variant | Exon 3 of 15 | XP_047287386.1 | 
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.0000329  AC: 5AN: 152172Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.0000795  AC: 20AN: 251478 AF XY:  0.000103   show subpopulations 
GnomAD4 exome  AF:  0.0000670  AC: 98AN: 1461892Hom.:  0  Cov.: 32 AF XY:  0.0000660  AC XY: 48AN XY: 727248 show subpopulations 
Age Distribution
GnomAD4 genome   AF:  0.0000329  AC: 5AN: 152172Hom.:  0  Cov.: 32 AF XY:  0.0000269  AC XY: 2AN XY: 74352 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
Hereditary spastic paraplegia 3A    Uncertain:3 
This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 66 of the ATL1 protein (p.Glu66Gln). This variant is present in population databases (rs200314808, gnomAD 0.01%). This missense change has been observed in individual(s) with hereditary sensory neuropathy, type 1 (PMID: 21194679). ClinVar contains an entry for this variant (Variation ID: 30580). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on ATL1 protein function. Experimental studies have shown that this missense change does not substantially affect ATL1 function (PMID: 21194679). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
Neuropathy, hereditary sensory, type 1D    Pathogenic:1 
- -
not provided    Uncertain:1 
Identified in a patient with hereditary sensory neuropathy type I in published literature; however, in vitro studies demonstrated no significant change in GTPase activity compared to control (Guelly et al., 2011); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 23334294, 21194679) -
Inborn genetic diseases    Benign:1 
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at